glp 1 analogları GLP-1 receptor agonists Glucagon-like peptide-1 receptor: mechanisms and
Description
Invest in clinical development that supports new, high-need indications that can improve the brands value proposition, especially in restrictive channels like Medicare
Its hard to avoid glucagon-like peptide-1 (GLP-1) drugs these days with all the TV commercials and pop-up ads
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026
He discovered GLP-1, which helped pave the way for transformative diabetes and obesity therapies, and he was an ASBMB member for 25 years.
Total Carbohydrates
this article explains how Ypsomed has also applied its sustainability principles to larger-volume delivery.
